Payment overview · 2025
General Payments
$351.17
16 reported records · 8 companies
Healthcare provider profile · identity verified
Megan E Brown, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ABILENE, KS · NPI 1821389180
Verified facts
What the public records show
CMS Open Payments records show Megan E Brown, M.D. received $351.17 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.19 | 30.2% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $85.96 | 24.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.01 | 10.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.61 | 10.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.80 | 9.1% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.75 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.88 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.97 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.17 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $106.19 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $85.96 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $85.34 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 37 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
56 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 83 |
| Lisinopril | Lisinopril | 376 | 85 |
| Omeprazole | Omeprazole | 255 | 53 |
| Gabapentin | Gabapentin | 250 | 43 |
| Simvastatin | Simvastatin | 246 | 49 |
| Potassium Chloride | Potassium Chloride | 239 | 55 |
| Losartan Potassium | Losartan Potassium | 223 | 46 |
| Metformin Hcl | Metformin Hcl | 207 | 44 |
| Furosemide | Furosemide | 188 | 42 |
| Celecoxib | Celecoxib | 184 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 30 |
| Montelukast Sodium | Montelukast Sodium | 152 | 32 |
| Atenolol | Atenolol | 150 | 30 |
| Trazodone Hcl | Trazodone Hcl | 137 | 29 |
| Glipizide Er | Glipizide | 131 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 26 |
| Xarelto | Rivaroxaban | 117 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 108 | 22 |
| Sertraline Hcl | Sertraline Hcl | 108 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 16 |
| Alprazolam | Alprazolam | 94 | suppressed |
| Spironolactone | Spironolactone | 94 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 17 |
| Tramadol Hcl | Tramadol Hcl | 88 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 56 |
| Famotidine | Famotidine | 83 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 17 |
| Lorazepam | Lorazepam | 81 | 22 |
| Chlorthalidone | Chlorthalidone | 79 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 16 |
| Meloxicam | Meloxicam | 74 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | suppressed |
| Prednisone | Prednisone | 61 | 36 |
| Bumetanide | Bumetanide | 60 | suppressed |
| Clonazepam | Clonazepam | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 56 | 40 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Nystatin | Nystatin | 46 | 15 |
| Carvedilol | Carvedilol | 45 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 37 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Metolazone | Metolazone | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Nystop | Nystatin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Probenecid | Probenecid | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.17 · 16 records | PFIZER INC. | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, EVENITY, Korlym, LEQVIO, MOUNJARO, PEDIARIX, PENMENVY, PREVNAR 20, Prolastin-C Liquid, REXULTI, SHINGRIX, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error